Active, not recruitingPhase 2NCT03529422
Durvalumab With Radiotherapy for Adjuvant Treatment of Intermediate Risk SCCHN
Studying Lymphoid interstitial pneumonia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- UNC Lineberger Comprehensive Cancer Center
- Principal Investigator
- Siddharth Sheth, DO MPHUNC Lineberger Comprehensive Cancer Center
- Intervention
- Durvalumab(drug)
- Enrollment
- 18 enrolled
- Eligibility
- 18 years · All sexes
- Timeline
- 2019 – 2026
Study locations (3)
- University Of Alabama At Birmingham, Birmingham, Alabama, United States
- UNC Lineberger Comprehensive Cancer Center, Chapel Hill, North Carolina, United States
- Medical University of South Carolina - Hollings Cancer Center, Charleston, South Carolina, United States
Collaborators
AstraZeneca
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT03529422 on ClinicalTrials.govOther trials for Lymphoid interstitial pneumonia
Additional recruiting or active studies for the same condition.